NAVLE Primates

Primate Viral Hepatitis A and B Study Guide

📅 March 28, 2026 ⏱ 20 min read
Viral hepatitis in non-human primates (NHPs) represents a significant zoonotic disease and research model challenge.

Overview and Clinical Importance

Viral hepatitis in non-human primates (NHPs) represents a significant zoonotic disease and research model challenge. Both hepatitis A virus (HAV) and hepatitis B virus (HBV) can naturally infect various primate species, making this topic crucial for veterinarians working with captive primates, zoo animals, and laboratory animals. Understanding these infections is essential for both animal health management and public health protection of personnel in contact with non-human primates.

Primate Group Susceptible Species Clinical Presentation
Great Apes Chimpanzees (Pan troglodytes) Usually mild or subclinical; complete recovery
Old World Monkeys Rhesus macaques, cynomolgus macaques, African green monkeys Mild to subclinical; seroconversion occurs
New World Monkeys Marmosets (Callithrix jacchus), tamarins, owl monkeys, squirrel monkeys Susceptible; disease milder than in humans

Hepatitis A Virus (HAV) in Primates

Etiology and Pathophysiology

Virus Classification: HAV is a 27-nm, non-enveloped, positive-sense single-stranded RNA virus belonging to the family Picornaviridae, genus Hepatovirus. The virus has similar characteristics to enteroviruses and is highly stable in the environment.

Transmission Route: HAV is transmitted primarily via the fecal-oral route. Contaminated food, water, and direct contact with infected individuals are common sources. Peak viral shedding in feces (up to 10^9 virions per gram) occurs before the onset of clinical signs, making infection control challenging.

Pathogenesis: Following oral ingestion, HAV replicates in hepatocytes. The virus is excreted in bile and shed in feces. Viremia occurs during the acute phase. Liver injury is primarily immune-mediated rather than directly cytopathic. T-cell mediated immunity, particularly CD4+ helper T cells in primate models, is crucial for viral clearance.

Species Susceptibility

HAV has a broader host range among non-human primates compared to HBV. Both Old World and New World monkeys are susceptible:

NAVLE TipHAV has the WIDEST host range among hepatitis viruses in primates - both Old World and New World monkeys are susceptible. In contrast, HBV and HCV are restricted primarily to great apes. On the exam, if you see a New World monkey with hepatitis, think HAV over HBV.

Clinical Signs and Diagnosis

Clinical Presentation

Incubation Period: 15-50 days (average 28 days)

Clinical Signs in Non-Human Primates: HAV infection in primates is typically milder or subclinical compared to humans. When signs occur, they include:

  • Lethargy and anorexia
  • Jaundice (icterus) - less common than in humans
  • Vomiting and diarrhea
  • Hepatomegaly (mild)
  • Elevated liver enzymes (AST, ALT)

Diagnostic Approach

High-YieldFor the NAVLE, remember the serological timeline: IgM anti-HAV = ACUTE infection (current/recent), IgG anti-HAV = PAST infection or immunity. Fecal shedding peaks BEFORE clinical signs appear, making infected animals highly contagious during the incubation period.

Pathological Findings

Gross Pathology: Mild hepatomegaly with yellow discoloration (icterus) of liver and other tissues. In most primate cases, changes are subtle.

Histopathology: Characteristic features of HAV hepatitis in primates include:

  • Portal inflammation - lymphocytic infiltration predominates in periportal areas
  • Hepatocellular necrosis - mainly in periportal zones
  • Ballooning degeneration of hepatocytes
  • Acidophilic bodies (Councilman bodies) - apoptotic hepatocytes
  • Cholestasis (bile stasis) in canaliculi
  • Complete recovery typical - NO chronic disease or fibrosis

Treatment and Prevention

Treatment

Prevention and Control

  • Vaccination: Inactivated HAV vaccine is available and effective in primates. Recommended for high-risk colonies and personnel.
  • Isolation: Isolate infected animals for at least 2 weeks after onset of jaundice.
  • Hygiene: Strict hand hygiene, environmental sanitation, proper food and water handling.
  • PPE: Personal protective equipment for handlers, especially during peak shedding period.
  • Quarantine: Quarantine new arrivals and screen for HAV antibodies before introduction to colony.
Diagnostic Test Clinical Significance
IgM anti-HAV Detectable 5-10 days before clinical signs, persists for 6 months. Indicates current or recent infection.
IgG anti-HAV Appears at onset of illness, persists for life. Indicates past infection or immunity.
ALT/AST Markedly elevated during acute phase. ALT more specific for hepatocellular injury.
RT-PCR Detects viral RNA in serum or feces. Highly specific but expensive; used for molecular epidemiology.
Fecal HAV Detection Peak shedding before jaundice; can shed for months in young animals. Not commercially available.

Hepatitis B Virus (HBV) in Primates

Etiology and Pathophysiology

Virus Classification: HBV is a partially double-stranded DNA virus belonging to the family Hepadnaviridae. The virus is approximately 42 nm in diameter (Dane particle) with a lipid envelope containing hepatitis B surface antigen (HBsAg).

Transmission Route: HBV is transmitted via the parenteral route - through blood, body fluids, and sexual contact. Vertical transmission from dam to offspring can occur. Unlike HAV, HBV is NOT primarily transmitted via the fecal-oral route.

Pathogenesis: HBV has tropism for hepatocytes. The virus enters cells via the sodium taurocholate cotransporting polypeptide (NTCP) receptor. Viral replication occurs in the nucleus, producing covalently closed circular DNA (cccDNA) that serves as a template. HBV can cause both acute and chronic infection in susceptible primate species. Liver injury is primarily immune-mediated rather than directly cytopathic.

Species Susceptibility

HBV has a much narrower host range than HAV, primarily restricted to great apes:

Clinical Signs and Diagnosis

Clinical Presentation

Incubation Period: 30-180 days (average 60-90 days) - MUCH LONGER than HAV

Acute HBV Infection: Similar to HAV but less severe in primates. Most infections are subclinical or mild:

  • Lethargy, anorexia
  • Jaundice (uncommon)
  • Elevated liver enzymes (AST, ALT)
  • Most cases resolve spontaneously

Chronic HBV Infection: Occurs in 5-10% of infected chimpanzees (similar to humans). Defined by HBsAg positivity greater than 6 months. Chronically infected animals:

  • Usually asymptomatic carriers
  • Can develop chronic hepatitis with persistent inflammation
  • Risk of cirrhosis and hepatocellular carcinoma (lower than in humans)
  • Source of infection to others

Serological Markers and Interpretation

NAVLE TipKnow the 'window period' - when HBsAg has cleared but anti-HBs has not yet appeared. During this time, anti-HBc IgM may be the ONLY detectable marker. Also remember: anti-HBc does NOT equal immunity (that's anti-HBs). HBV DNA greater than 6 months with persistent HBsAg = chronic infection.

Pathological Findings

Gross Pathology: In acute infection, liver may appear normal or show mild enlargement. Chronic infection may show varying degrees of fibrosis and, rarely, cirrhosis.

Histopathology of Acute HBV:

  • Lobular disarray - involves ENTIRE lobular parenchyma (unlike HAV which is periportal)
  • Hepatocyte necrosis - more severe in lobular centers
  • Spotty necrosis and acidophilic bodies
  • Ground-glass hepatocytes (cytoplasm filled with HBsAg)
  • Portal inflammation less conspicuous than HAV
  • Interface hepatitis (piecemeal necrosis) at portal-parenchymal junction

Histopathology of Chronic HBV:

  • Persistent portal and lobular inflammation
  • Fibrosis - progressive bridging fibrosis can develop
  • Ground-glass hepatocytes (diagnostic for HBV)
  • Eventual cirrhosis in some cases

Key Difference HAV vs HBV: HAV = Periportal inflammation, NO chronic disease. HBV = Pan-lobular involvement, CAN cause chronic hepatitis and cirrhosis.

Treatment and Prevention

Treatment

Prevention and Control

  • Vaccination: Recombinant HBV vaccine is highly effective. Recommended for great apes in captivity and high-risk personnel.
  • Screening: Screen new arrivals and breeding animals for HBsAg and anti-HBc.
  • Biosafety: Universal precautions, avoid needlestick injuries, proper sharps disposal, PPE.
  • Isolation: Segregate chronic carriers. Minimize blood exposure during procedures.
  • Post-exposure Prophylaxis: HBV immune globulin (HBIG) and vaccination for personnel exposed to HBV-positive animals.
Treatment Category Management Strategy
Supportive Care Primary approach: Rest, adequate hydration, nutritional support with easily digestible foods
Symptomatic Treatment Antiemetics for nausea/vomiting, fluid therapy for dehydration, monitoring liver function
Antiviral Therapy NO specific antiviral treatment available. HAV is self-limiting.
Prognosis Excellent - complete recovery expected. NO chronic hepatitis develops. Fulminant hepatitis is rare.

Zoonotic Potential and Public Health

Cross-Species Transmission

Human to Primate: Both HAV and HBV can be transmitted from humans to non-human primates. Historical outbreaks have occurred in primate colonies from infected handlers. Veterinarians, zookeepers, and laboratory personnel pose transmission risk.

Primate to Human: Documented cases of HAV transmission from chimpanzees to humans exist. HBV transmission from primates to humans is theoretically possible but not well-documented. Personnel working with great apes should be vaccinated against both HAV and HBV.

Occupational Health Recommendations

  • Pre-employment vaccination for HAV and HBV
  • Serologic screening to document immunity
  • Avoid contact when personnel have active infections
  • Standard and transmission-based precautions
  • Post-exposure evaluation and prophylaxis protocols
High-YieldFor the NAVLE, remember that working with non-human primates requires vaccination against HAV and HBV. Primates are susceptible to human hepatitis viruses, making this a bidirectional zoonotic risk. Always emphasize prevention through vaccination and biosafety practices.
Primate Group Species Prevalence Clinical Notes
Great Apes Chimpanzees (Pan troglodytes) 24-29% in wild populations Primary model species; can develop chronic infection
Great Apes Gorillas (Gorilla gorilla) Lower prevalence than chimpanzees Susceptible to both human and indigenous HBV
Great Apes Orangutans (Pongo pygmaeus) 15% prevalence reported Indigenous HBV variants exist
Lesser Apes Gibbons (Hylobates spp.) 23-33% prevalence Highly susceptible; endemic HBV strains
Old World Monkeys Baboons, macaques Rare; minimal susceptibility Experimental models require immunosuppression
New World Monkeys All species NOT susceptible NTCP receptor incompatibility

Summary Comparison: HAV vs HBV in Primates

Marker What it Indicates Timing Clinical Significance
HBsAg Hepatitis B surface antigen Appears before symptoms Current infection. If persists greater than 6 months = chronic carrier
Anti-HBs Antibody to surface antigen After recovery or vaccination Immunity and protection
HBeAg Hepatitis B e antigen During active replication High infectivity; active viral replication
Anti-HBc IgM Antibody to core antigen During acute infection Indicates recent acute infection (within 6 months)
Anti-HBc IgG Antibody to core antigen Lifelong after infection Past or current infection (does NOT confer immunity)
HBV DNA (PCR) Viral DNA in serum During active infection Confirms viral replication; quantifies viral load
Treatment Category Management Strategy
Acute HBV Supportive care: Rest, hydration, nutritional support. Most cases self-limiting. Monitor liver function.
Chronic HBV Antiviral therapy: Nucleoside/nucleotide analogues (tenofovir, entecavir) suppress viral replication. Long-term therapy often required.
Monitoring Serial ALT, HBV DNA levels, HBsAg, anti-HBs. Ultrasound for cirrhosis/HCC screening in chronic cases.
Prognosis Acute: Excellent, 90-95% clear infection. Chronic: Variable; can develop cirrhosis and HCC. Severity consistently milder in primates than humans.
Feature Hepatitis A Virus (HAV) Hepatitis B Virus (HBV)
Virus Type RNA virus, Picornaviridae, 27 nm DNA virus, Hepadnaviridae, 42 nm
Transmission Fecal-oral route Parenteral, blood, body fluids
Incubation 15-50 days (mean 28) 30-180 days (mean 60-90)
Host Range WIDE - Old and New World monkeys, great apes NARROW - Great apes, gibbons only
Clinical Course Acute only, self-limiting, mild in primates Acute or chronic (5-10% become carriers)
Chronic Infection DOES NOT OCCUR CAN OCCUR (HBsAg positive greater than 6 months)
Histopathology Periportal inflammation predominates Pan-lobular involvement, ground-glass hepatocytes
Diagnosis IgM anti-HAV (acute), IgG anti-HAV (immunity) HBsAg, anti-HBs, anti-HBc, HBeAg, HBV DNA
Treatment Supportive only; no antivirals Supportive for acute; antivirals for chronic
Vaccination Inactivated vaccine available and effective Recombinant vaccine available and effective
Zoonotic Risk Bidirectional - documented human-primate transmission Bidirectional - theoretical but less documented

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →

Related Articles

NAVLE

Primate Tuberculosis Study Guide

 NAVLE

Simian Immunodeficiency Virus (SIV) and Simian AIDS – NAVLE Study Guide

 NAVLE

Primate Toxoplasmosis Study Guide